Back to results
US 9,956,250 B2Granted
Use of allogeneic interstitial vessel-layer cell and allogeneic mesenchymal progenitor cell for preventing or treating osteoarthritis
AssigneesCellular Biomedicine Group (Shanghai) Ltd, Cellular Biomedicine Group (Wuxi) Ltd.
InventorsWei Cao, Xiaoling Zeng, Mohammad Abdul Kaium, Yujie Zhou
Life of this patent
Estimating the term…
Abstract
Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells.
Claims12
A method for preparing a pharmaceutical composition for preventing and/or treating osteoarthritis, comprising:
- mixing allogeneic interstitial vessel-layer cells (SVF) and allogeneic mesenchymal progenitor cells (haMPCs) with a pharmaceutically acceptable carrier,
- wherein the allogeneic mesenchymal progenitor cells have one or more features selected from the group consisting of
- (i) more than 95% of the cells having surface antigen CD90,
- (ii) more than 95% of the cells having surface antigen CD73,
- (iii) more than 95% of the cells having surface antigen CD29, and
- (iv) more than 95% of the cells having surface antigen CD49d,
- wherein the allogeneic interstitial vessel-layer cells have one or more features selected from the group consisting of
- (a) more than 30% of the cells having surface antigen CD29,
- (b) more than 50% of the cells having surface antigen CD73,
- (c) more than 85% of the cells having surface antigen CD49d, and
- (d) more than 55% of the cells having surface antigen CD90,
- wherein the haMPCs are prepared by a method including:
- digesting an adipose tissue by an enzyme to obtain stromal vascular fraction cells;
- inoculating the stromal vascular fraction cells into a culture flask to obtain adherent cells;
- culturing the adherent cells for 5-7 days to obtain primary adherent cells;
- and
- subjecting the primary adherent cells to passage at a ratio of 1:1-2 and culturing for 2-3 weeks.
14 more elements
A method for preparing a pharmaceutical composition for preventing and/or treating osteoarthritis, comprising:
- mixing allogeneic interstitial vessel-layer cells (SVF) and allogeneic mesenchymal progenitor cells (haMPCs) with pharmaceutically acceptable carrier;
- wherein the allogeneic mesenchymal progenitor cells have one or more features selected from the group consisting of
- (i) more than 95% of the cells having surface antigen CD90,
- (ii) more than 95% of the cells having surface antigen CD73,
- (iii) more than 95% of the cells having surface antigen CD29, and
- (iv) more than 95% of the cells having surface antigen CD49d,
- wherein the haMPCs are prepared by a method including:
- digesting an adipose tissue by an enzyme to obtain stromal vascular fraction cells;
- inoculating the stromal vascular fraction cells into a culture flask to obtain adherent cells;
- culturing the adherent cells for 5-7 days to obtain primary adherent cells;
- and
- subjecting the primary adherent cells to passage at a ratio of 1:1-2 and culturing for 2-3 weeks.
9 more elements
A method for preparing a pharmaceutical composition for preventing and/or treating osteoarthritis, comprising:
- mixing allogeneic interstitial vessel-layer cells (SVF) and allogeneic mesenchymal progenitor cells (haMPCs) with a pharmaceutically acceptable carrier,
- wherein the allogeneic mesenchymal progenitor cells have:
- (i) more than 95% of the cells having surface antigen CD90;
- (ii) more than 95% of the cells having surface antigen CD73;
- (iii) more than 95% of the cells having surface antigen CD29;
- (iv) more than 95% of the cells having surface antigen CD49d;
- (v) less than 2% of the cells having surface antigen HLA-DR;
- (vi) less than 2% of the cells having surface antigen Actin;
- (vii) less than 2% of the cells having surface antigen CD34;
- (viii) less than 2% of the cells having surface antigen CD45;
- and
- (ix) less than 2% of the cells having surface antigen CD14
- wherein the allogeneic interstitial vessel-layer cells have:
- (a) more than 30% of the cells having surface antigen CD29;
- (b) more than 50% of the cells having surface antigen CD73;
- (c) more than 85% of the cells having surface antigen CD49d;
- (d) more than 55% of the cells having surface antigen CD90
- (e) less than 85% of the cells having surface antigen CD34;
- and
- (f) less than 15% of the cells having surface antigen CD45,
- wherein the haMPCs are prepared by a method including:
- digesting an adipose tissue by an enzyme to obtain stromal vascular fraction cells;
- inoculating the stromal vascular fraction cells into a culture flask to obtain adherent cells;
- culturing the adherent cells for 5-7 days to obtain primary adherent cells;
- and
- subjecting the primary adherent cells to passage at a ratio of 1:1-2 and culturing for 2-3 weeks.
23 more elements
Dependencies are inferred from the claim text.